Johnson Johnson INNOVATION

Antonio Gómez PhD

DRUG DISCOVERY PHARMA-BIOTECH FORUM Sevilla, September 26th 2018

Johmon-Johmon INNOVATION

Johnson & Johnson is the largest and most diversified healthcare company in the world

More than *130* years creating *value* through *innovation*


Three business segments: pharmaceuticals, medical devices, consumer


>250 Operating Companies


Selling products in more than 175 countries


Over 130,000 employees worldwide


Johmon-Johmon INNOVATION















Our main initiative in Spain: I2D2

- Call for projects with disruptive innovation en las areas of interest of J&J
- *New model* in public-private partnership
- Co-funded between Janssen Spain, Xunta de Galicia and Kaertor









I2D2 Status

- More than 150 Expressions of Interest received
- *Three projects selected* to proceed to the incubation stage

QUIMATR X Selective HDAC6 inhibitors for neurodegenerative conditions



Inhibition of p38 γ as a treatment for steatosis



Allosteric modulators of the dopamine D1 receptor for PD

Thank you

#MakeTheConnection

@jnjinnovation.com

agomez2@its.jnj.com



The patients are waiting

Johmon-Johmon INNOVATION